All Type of News
Domestic Firm Implements Accounting Change for Expected Sales Return
Youngjin Pharmaceutical announced on February 18th that it has implemented a change in the company's financial accounting standards, in the area of revenue and profit recognitions as related to an expected sales retur...
OTC Makers Consider Different Pricing Strategies to Boost Revenue
As the domestic over-the-counter (OTC) product sales are continuing to decline for an extended period of time, the pharmaceutical firms are implementing different marketing and pricing strategies to gain higher sales ...
KSE-Listed Firms Show Strong Financial Results for Three Quarters
The 3rd quarter year-to-date (YTD) financial results for KSE-listed pharmaceutical firms, with their fiscal year ending March 2005, collectively show over 12 percent growth in revenue, propelled by aggressive ma...
Prescription Refill System, Substitution Dispensary Practice Suggested
After over four years since the implementation of pharmaceutical regulation that has separated dispensary from medical practices, Rep. Chang Bok-shim of the ruling Uri Party recommended a number of follow-up measures ...
KPMA Aims to Promote Global Competitiveness for Domestic Manufacturers
The Korea Pharmaceutical Manufacturer Association (KPMA) held a board meeting last week to finalize the association's main operating objectives for the current year, under an overall initiative to gain a competitive e...
Expedited Patent Examination Period from 21 to 10 Months Under Plan
The Korea Intellectual Property Office (KIPO) is looking to improve the patent examination turnaround period from the current 21 months to 10 months by the end of Year 2006.
Reflective of the above initiative, the ...
Foreign Trade Information Repository Now Established
The Korea Health Industry Development Institute (KHIDI) announced this week of an establishment of international trade information repository, detailing the import and export trade activities by eight specific foreign...
Topamax Approved for Migraine Headache Prevention
The Korea Food and Drug Administration (KFDA) has recently approved Topamax (active ingredient: topiramate), an anti-seizure medication marketed by Janssen Korea, for prevention of migraine headaches in adults.
Th...
Lifecord Stat-Korea Makes Partnership Agreement with MDS Pharma Services
Lifecord Stat-Korea (LSK), a domestic CRO (contract research organization) company, recently made a business partnership agreement with MDS Pharma Services, a global provider of drug discovery and development solution...
KFDA Issues Revised Market Approval Specification for Gemzar
The Korea Food and Drug Administration (KFDA) recently issued a revised approval specification for Lilly Korea's Gemzar Inj. 200mg (active ingredient: gemcitabine hydrochloride), a chemotherapy drug for treatment of c...
